ANONYMOUS: "Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)", CLINICALTRIALS.GOV, 28 August 2017 (2017-08-28), pages 1 - 8, XP055564774, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT02955602?V_21=View#StudyPageTop> [retrieved on 20190305] (B8)

ANONYMOUS: "Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)", CLINICALTRIALS.GOV, 30 January 2017 (2017-01-30), pages 1 - 10, XP055564778, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT02609048?V_31=View#StudyPageTop> [retrieved on 20190305] (B8)

WO-A1-2015/143178 (B8)

MARINA G. SILVEIRA ET AL: "Investigational drugs in phase II clinical trials for primary biliary cholangitis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 26, no. 10, 24 August 2017 (2017-08-24), UK, pages 1115 - 1121, XP055523264, ISSN: 1354-3784, DOI: 10.1080/13543784.2017.1371135 (B8)

VINOD S HEGADE ET AL: "A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis", FRONTLINE GASTROENTEROLOGY, vol. 7, no. 3, 26 August 2015 (2015-08-26), pages 158 - 166, XP055564100, ISSN: 2041-4137, DOI: 10.1136/flgastro-2015-100618 (B8)

D JONES ET AL: "A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA)", CYMABAY THERAPEUTICS, February 2017 (2017-02-01), pages 1 - 16, XP055564310, Retrieved from the Internet <URL:https://content.equisolve.net/cymabay/media/2ab054a43f96c6154a9f5ce9f2355a4d.pdf> [retrieved on 20190304] (B8)